Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	1387865 PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	NICE nod for Darzalex with lenalidomide and dexamethasone - 12 months ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets - 6 days ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 9 days ago Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma - 15 days ago Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies - about 2 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 2 months ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - 8 months ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - 9 months ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - 10 months ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - 10 months ago T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers - 11 months ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - 11 months ago Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer - 11 months ago
3	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - about 1 month ago Brentuximab Vedotin Shows 37% Reduction in Risk of Death for DLBCL - 3 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 6 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - 9 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - 10 months ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - 11 months ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - 12 months ago
4	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Breakthrough Therapy Designation to DS-8201a and T-DXd to Treat Metastatic Breast Cancer - about 1 month ago New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - about 1 month ago FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 3 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 6 months ago Utidelone Injectable Granted FDA Orphan Drug Designation for Breast Cancer Brain Metastasis - 6 months ago
5	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer - about 2 months ago STAT+: Results on Novartis prostate cancer therapy could expand its use - 11 months ago STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial - 12 months ago
6	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Are T-DXd Results in HER2-Low/Ultralow Breast Cancer Practice-Changing? - 3 months ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - 7 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 9 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 9 months ago Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer - 9 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - 9 months ago KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer - 9 months ago T-DXd Could Be 'Practice-Changing' in HER2-Expressing Gynecologic Cancers - 10 months ago The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer - 11 months ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 4 months ago
8	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med - 5 months ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 6 months ago
10	Pharmacy Times Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Pharmacy Focus: Oncology Edition- Latest Updates in Non-Small Cell Lung Cancer Treatment - 7 months ago

Journalists covering docetaxel